Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

CUSIP: 98422T100

Q2 2025 13F Holders as of 30 Jun 2025

Security identity
Shares outstanding
6,426,426
Holder snapshot
Share change
+1,267,057
Reported price per share
$0.68
Number of holders
35
Value change
+$854,217
Number of buys
9
Number of sells
16

Security key

98422T100

Report period

Q2 2025

Institutions

35

Top holders

10

Ownership snapshot

Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Lead holder
AbbVie Inc.
13D/G signal
AbbVie Inc.
Evidence rows
15
Latest as of
31 Mar 2025
13D/G 13F 3/4/5 Lead comparable stake: 9% 13D/G row: AbbVie Inc. Showing 1-6 of 15 holder rows.
Holder Evidence Ownership % Position 12M Net Δ As of
AbbVie Inc.
13D/G
9%
$3,304,348
4,347,826 shares
$0 11 Feb 2025
GILEAD SCIENCES, INC.
13F
Company
13F
142%
$6,595,989
9,105,451 shares
31 Mar 2025
Bain Capital Life Sciences Investors, LLC
13F 3/4/5
Company · 10%+ Owner
71%
$3,308,202
4,566,817 shares
31 Mar 2025
Merck & Co., Inc.
13F
Company
13F
23%
$1,074,834
1,483,758 shares
31 Mar 2025
TAKEDA PHARMACEUTICAL CO LTD
3/4/5 13F
10%+ Owner · Company
23%
from 13F
$1,224,350
1,475,121 shares
26 Oct 2021
MORGAN STANLEY
13F
Company
13F
18%
$837,289
1,155,838 shares
31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
35
Shares
23,795,263
Rows available
35
Investor Option Weight % Change % Reported value * Price Shares Share Change Activity Report Period

* Reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that failed the local validity check.

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
35
Q2 2025 holders
35
Holder diff
0
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 value Q2 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .